Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling
| dc.contributor.author | Ejalu David Livingstone | |
| dc.contributor.author | Irioko Aaron | |
| dc.contributor.author | Kirabo Rhoda | |
| dc.contributor.author | Mukose Aggrey David | |
| dc.contributor.author | Ekirapa Elizabeth | |
| dc.contributor.author | Kagaayi Joseph | |
| dc.date.accessioned | 2023-07-18T14:45:54Z | |
| dc.date.available | 2023-07-18T14:45:54Z | |
| dc.date.issued | 2022-08-08 | |
| dc.description.abstract | To determine the cost-effectiveness of Xpert Omni compared with Xpert MTB/Rif for point-of-care diagnosis of tuberculosis among presumptive cases in a low-resource, high burden facility. Cost-effectiveness analysis from the provider’s perspective. Setting A low-resource, high tuberculosis burden district in Eastern Uganda. Participants A provider’s perspective was used, and thus, data were collected from experts in the field of tuberculosis diagnosis purposively selected at the local, subnational and national levels. A decision analysis model was contracted from TreeAge comparing Xpert MTB/Rif and Xpert Omni. Cost estimation was done using the ingredients’ approach. One-way deterministic sensitivity analyses were performed to identify the most influential model parameters. Outcome measure The outcome measure was incremental cost per additional test diagnosed expressed as the incremental cost-effectiveness ratio. The total cost per test for Xpert MTB/Rif was US$14.933. Cartridge and reagent kits contributed to 67% of Xpert MTB/Rif costs. Sample transport costs increased the cost per test of Xpert MTB/Rif by $1.28. The total cost per test for Xpert Omni was $16.153. Cartridge and reagent kits contributed to over 71.2% of Xpert Omni’s cost per test. The incremental costeffectiveness ratio for using Xpert Omni as a replacement for Xpert MTB/Rif was US$30.73 per additional case detected. There was no dominance noted in the cost-effectiveness analysis, meaning no strategy was dominant over the other. The use of Xpert Omni at the point-of-care health facility was more effective but with an increased cost compared with Xpert MTB/Rif at the centralised referral testing facility. | en_US |
| dc.identifier.doi | https://doi.org/10.1136/bmjopen-2021-059823 | |
| dc.identifier.issn | Online ISSN: 2044-6055 | |
| dc.identifier.issn | Print ISSN: 2044-6055 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12280/3036 | |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ | en_US |
| dc.relation.ispartofseries | BMJ Open;2022;12:e059823 | |
| dc.title | Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling | en_US |
| dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Ejalu-Health-Article-2022-Cost-effectiveness.pdf
- Size:
- 1.13 MB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description:
